Heterocyclic compound and use thereof
US11702419B2 · kind B2 · utility
1Cited by
4References
18Claims
0Family size
Assignee
Inventors
- Yuya Oguro
- Shigemitsu Matsumoto
- Takeshi Wakabayashi
- Norihito Tokunaga
- Taku Kamei
- Mitsuhiro Ito
- Satoshi Mikami
- Masaki Seto
- Shinji Morimoto
- Shinji Nakamura
- Sachie TAKASHIMA
- Masataka Murakami
- Masaki DAINI
- Makoto Kamata
- Minoru Nakamura
- Yasufumi Wada
- Hiroyuki KAKEI
- Kazuaki Takami
- Taisuke Tawaraishi
- Jumpei Aida
- Kouichi Iwanaga
- Satoshi Yamamoto
Key dates
| Filing date | Mar 15, 2021 |
| Grant date | Jul 18, 2023 |
| Priority date | — |
| Expiry date | May 18, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.